These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34197279)

  • 1. Next generation sequencing in therapy-related myeloid neoplasms compared to
    Claerhout H; Vranckx H; Lierman E; Michaux L; Boeckx N
    Acta Clin Belg; 2022 Jun; 77(3):658-663. PubMed ID: 34197279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
    Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
    Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
    Nardi V; Winkfield KM; Ok CY; Niemierko A; Kluk MJ; Attar EC; Garcia-Manero G; Wang SA; Hasserjian RP
    J Clin Oncol; 2012 Jul; 30(19):2340-7. PubMed ID: 22585703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.
    Ronaghy A; Hu S; Tang Z; Wang W; Tang G; Loghavi S; Li S; Thakral B; Medeiros LJ; Muzzafar T
    Mod Pathol; 2021 Feb; 34(2):300-313. PubMed ID: 33110238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
    Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.
    Shah MV; Mangaonkar AA; Begna KH; Alkhateeb HB; Greipp P; Nanaa A; Elliott MA; Hogan WJ; Litzow MR; McCullough K; Tefferi A; Gangat N; Patnaik MM; Al-Kali A; He R; Chen D
    Blood Cancer J; 2022 Jul; 12(7):106. PubMed ID: 35803921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
    Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
    Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
    Higgins A; Shah MV
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
    Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
    Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
    Fabiani E; Fianchi L; Falconi G; Boncompagni R; Criscuolo M; Guidi F; La Brocca A; Hohaus S; Leone G; Voso MT
    Leuk Lymphoma; 2014 Jul; 55(7):1538-43. PubMed ID: 24047476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.